Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform
Open Access
Abstract
The COVID-19 pandemic has reached over 100 million worldwide. Due to the multi-targeted nature of the virus, it is clear that drugs providing anti-COVID-19 effects need to be developed at an accelerated rate, and a combinatorial approach may stand to be more successful than a single drug therapy. Among several targets and pathways that are under investigation, the renin-angiotensin system (RAS) and specifically angiotensin-converting enzyme (ACE), and Ca2+-mediated SARS-CoV-2 cellular entry and replication are noteworthy. A combination of ACE inhibitors and calcium channel blockers (CCBs), a critical line of therapy for pulmonary hypertension, has shown therapeutic relevance in COVID-19 when investigated independently. To that end, we conducted in silico modeling using BIOiSIM, an AI-integrated mechanistic modeling platform by utilizing known preclinical in vitro and in vivo datasets to accurately simulate systemic therapy disposition and site-of-action penetration of the CCBs and ACEi compounds to tissues implicated in COVID-19 pathogenesis.Keywords
All Related Versions
This publication has 74 references indexed in Scilit:
- BDDCS Applied to Over 900 DrugsThe AAPS Journal, 2011
- Highly Pathogenic H5N1 Avian Influenza Virus Induces Extracellular Ca 2+ Influx, Leading to Apoptosis in Avian CellsJournal of Virology, 2010
- General approach for the calculation of tissue to plasma partition coefficientsToxicology in Vitro, 2008
- Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterionsJournal of Pharmaceutical Sciences, 2006
- Physiologically Based Pharmacokinetic Modeling 1: Predicting the Tissue Distribution of Moderate-to-Strong BasesJournal of Pharmaceutical Sciences, 2005
- Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolismBiochemical Journal, 2004
- Dose Linearity of Lacidipine Pharmacokinetics After Single and Repeated Oral Doses in Healthy VolunteersClinical Pharmacokinetics, 2003
- In vitro and in vivo assessment of cellular permeability and pharmacodynamics of S‐nitrosylated Captopril, a nitric oxide donorBritish Journal of Pharmacology, 2001
- Pharmacokinetics of lisinoprilThe American Journal of Medicine, 1988
- Pharmacokinetics of (+)‐, (‐)‐ and (+/‐)‐verapamil after intravenous administration.British Journal of Clinical Pharmacology, 1984